SCHEMBL301074

SCHEMBL301074

NC(=O)CC[C@H](N)C(=O)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.67
BLM P54132 1/20 0.67
PMP22 Q01453 1/20 0.67
KMT2A Q03164 1/20 0.67
GRIK1 P39086 3/20 0.44
CYP1A2 P05177 2/20 0.44
GRIA4 P48058 2/20 0.44
GRIK3 Q13003 2/20 0.44
GRIK5 Q16478 2/20 0.44
GSR P00390 2/20 0.44
GRIK2 Q13002 2/20 0.44
GRM1 Q13255 2/20 0.44
GRM2 Q14416 2/20 0.44
GRM8 O00222 1/20 0.44
GRM6 O15303 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRM5 P41594 1/20 0.44
GRIA1 P42261 1/20 0.44
GRIA2 P42262 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15295142 0.87 ALOX15 (0.68) ALOX15BLMPMP22KMT2AGRIK1
SCHEMBL16204518 0.84 BLM (0.64) ALOX15BLMPMP22KMT2AGRIK1
SCHEMBL30603189 0.83 ALOX15 (0.62) ALOX15BLMPMP22KMT2AGRIK1
SCHEMBL301073 0.83 CYP1A2 (0.65) ALOX15BLMPMP22KMT2AGRIK1
Glutamine SCHEMBL7176752 0.81 KMT2A (0.91) ALOX15BLMPMP22KMT2AGRIK1
Glutamine SCHEMBL29004304 0.81 KMT2A (0.91) ALOX15BLMPMP22KMT2AGRIK1
SCHEMBL31296037 0.81 KMT2A (0.67) ALOX15BLMPMP22KMT2AGRIK1
Glutamine SCHEMBL7176754 0.81 KMT2A (0.91) ALOX15BLMPMP22KMT2AGRIK1
Glutamine SCHEMBL411170 0.80 KMT2A (1.00) ALOX15BLMPMP22KMT2AGRIK1
Glutamine SCHEMBL411588 0.80 KMT2A (1.00) ALOX15BLMPMP22KMT2AGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272951-B1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives BAXTER INT (US) 2014-07-23 EP claimed
EP-2189523-B1 Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives BAXTER INT (US) 2012-01-04 EP claimed
EP-2272951-A1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives Baxter International Inc (US) 2011-01-12 EP claimed
EP-2189523-A1 Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives Baxter International Inc. (US) 2010-05-26 EP claimed
US-20200217281-A1 SYSTEM AND METHOD FOR ON-BOARD ELECTROCHEMICAL UPGRADING OF HYDROCARBON FUELS SAUDI ARABIAN OIL COMPANY (SA) 2020-07-09 US disclosed
CN-101090977-B Tripeptide and tetrapeptide thioethers TELIK INC 2013-04-10 CN disclosed
US-7777046-B2 Method of synthesis of a salt of N-acetyl-L-cysteinylcobalamin KENT STATE UNIVERSITY (US) 2010-08-17 US disclosed
WO-2009062136-A2 CONTROLLED DELIVERY OF INSULIN FROM THERMO-SENSITIVE POLYMER SOLUTION NDSU RESEARCH FOUNDATION (US) 2009-05-14 WO disclosed
EP-1833978-B1 TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS TELIK INC (US) 2008-10-08 EP disclosed
US-20080234489-A1 Method of synthesis of the sodium salt of N-acetyl-L-cysteinylcobalamin KENT STATE UNIVERSITY 2008-09-25 US disclosed
CN-101090977-A Tripeptide and tetrapeptide thioethers TELIK INC (US) 2007-12-19 CN disclosed
EP-1833978-A1 TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS TELIK, INC. (US) 2007-09-19 EP disclosed
US-5965789-A Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals AMERICAN RED CROSS (US) 1999-10-12 US disclosed
EP-0683676-A4 DIRECTED BIODISTRIBUTION OF SMALL MOLECULES. NEORX CORP (US) 1998-09-30 EP disclosed
WO-1998008566-A1 MANIPULATIONS OF NITROSATIVE AND OXIDATIVES STRESS IN THE TREATMENT OF DISEASE DUKE UNIVERSITY (US) 1998-03-05 WO disclosed
EP-0824593-A2 ENGINEERING PROTEIN POSTTRANSLATIONAL MODIFICATION IN TRANSGENIC ORGANISMS AMERICAN RED CROSS (US) 1998-02-25 EP disclosed
US-5607659-A Directed biodistribution of radiolabelled biotin using carbohydrate polymers NEORX CORPORATION (US) 1997-03-04 US disclosed
WO-1996034966-A2 ENGINEERING PROTEIN POSTTRANSLATIONAL MODIFICATION IN TRANSGENIC ORGANISMS AMERICAN RED CROSS (US) 1996-11-07 WO disclosed
EP-0683676-A1 DIRECTED BIODISTRIBUTION OF SMALL MOLECULES NEORX CORPORATION (US) 1995-11-29 EP disclosed
WO-1994017829-A1 DIRECTED BIODISTRIBUTION OF SMALL MOLECULES NEORX CORPORATION (US) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234489-A1 Method of synthesis of the sodium salt of N-acetyl-L-cysteinylcobalamin MMAB, CBS, NCLN ALOX15 1144/4885BLM 3415/4885PMP22 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.